Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 15/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085615 | 0.97 | AVPR1B (0.59) | AVPR1BCYP3A4HRH1HRH3SMN1; SMN2 | |
| SCHEMBL4089839 | 0.82 | AVPR1B (0.44) | AVPR1BHTR7 | |
| SCHEMBL75190 | 0.82 | AVPR1B (0.47) | AVPR1BCYP3A4HRH1HRH3SMN1; SMN2 | |
| SCHEMBL4077979 | 0.82 | AVPR1B (0.79) | AVPR1BCYP3A4 | |
| SCHEMBL4092300 | 0.82 | AVPR1B (0.77) | AVPR1BCYP3A4 | |
| SCHEMBL4408372 | 0.81 | AVPR1B (0.56) | AVPR1BCYP3A4HTR7 | |
| SCHEMBL4082841 | 0.81 | AVPR1B (0.80) | AVPR1BCYP3A4 | |
| SCHEMBL2888641 | 0.81 | AVPR1B (0.75) | AVPR1BCYP3A4 | |
| SCHEMBL4081704 | 0.81 | AVPR1B (0.82) | AVPR1BCYP3A4 | |
| SCHEMBL4407880 | 0.80 | AVPR1B (0.76) | AVPR1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431567-B2 | Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2066657-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008025735-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885CYP3A4 3668/4885HRH1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.